Treating opioid-induced constipation in patients taking other medications: Avoiding CYP450 drug interactions

Journal of Clinical Pharmacy and Therapeutics
Robert B RaffaJoseph V Pergolizzi

Abstract

When patients fail other treatment regimens and still suffer from pain sufficiently severe, opioid analgesics are appropriate and required. Unfortunately, constipation is a common adverse effect of opioids. Opioid-induced constipation (OIC) can be treated with one of the new peripherally acting µ-opioid receptor antagonist (PAMORA) agents. We summarize the mechanism of action of these drugs, with an emphasis on comparison of their potential for metabolic drug interactions. Internet sources were searched for English-language abstracts related to the topic. Emphasis was placed on the mechanism of the PAMORAs, their metabolic pathways, drugs co-administered with opioids and potential drug-drug interactions (particularly at the level of CYP450 isozyme drug metabolism). Each source was evaluated and synthesized into the review. PAMORAs dose-dependently antagonize the access of agonist molecules to opioid receptors, thereby directly eliminating or reducing OIC. But they differ from other opioid antagonists in that they are restricted to the periphery. Hence, they block constipation, but leave central opioid receptor-mediated pain relief undiminished. The PAMORAs have similar efficacy and safety profiles, but many pain patients have c...Continue Reading

References

Mar 20, 1979·Naunyn-Schmiedeberg's Archives of Pharmacology·E Beubler, F Lembeck
Dec 1, 1988·Journal of the American Geriatrics Society·R E GrymonpreP R Montgomery
Jan 1, 1981·European Journal of Clinical Pharmacology·K Selvig
Sep 1, 1996·The American Journal of Emergency Medicine·R M GoldbergS Wong
Jan 1, 1996·Pharmacology & Therapeutics·A De Luca, I M Coupar
Nov 14, 1997·Anesthesiology·D B MurphyM B Murphy
Jul 16, 1999·Clinical and Experimental Pharmacology & Physiology·M Connor, M D Christie
Jun 3, 2000·Annual Review of Pharmacology and Toxicology·P Y LawH H Loh
Jan 6, 2001·The Annals of Pharmacotherapy·D C SuhE R Hermes-De Santis
Jan 5, 2002·American Journal of Surgery·M Pappagallo
Aug 17, 2002·Journal of Pain and Symptom Management·Youn Seon Choi, J Andrew Billings
Mar 8, 2003·JAMA : the Journal of the American Medical Association·Jerry H GurwitzDavid W Bates
Apr 4, 2003·JAMA : the Journal of the American Medical Association·David N JuurlinkDonald A Redelmeier
Jun 17, 2003·PharmacoEconomics·Rosa Rodríguez-MonguióJoan Rovira
Nov 12, 2003·Archives of Internal Medicine·Matthew J BairKurt Kroenke
Mar 3, 2004·The Journal of Pharmacology and Experimental Therapeutics·Todd W VanderahPierre J-M Riviere
Jun 11, 2004·Annual Review of Biochemistry·Maria WaldhoerJennifer L Whistler
Sep 11, 2004·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·C SterniniA Kirchgessner
Sep 11, 2004·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·J D Wood, J J Galligan
Nov 24, 2004·The American Journal of Geriatric Pharmacotherapy·Emily R HajjarKenneth E Schmader
Mar 22, 2005·The Medical Journal of Australia·Christel L BurgessAnthony G Satti
Jan 4, 2006·Proceedings·C C Ogu, J L Maxa
Mar 24, 2006·Psychosomatic Medicine·Bruce A ArnowChris Hayward
Apr 28, 2006·Pharmacotherapy·C A Bond, Cynthia L Raehl
May 9, 2006·Gastroenterology·David GrundyJackie D Wood
May 30, 2006·The American Journal of Geriatric Pharmacotherapy·Julia K NguyenEunice Lo
Jun 27, 2006·Autonomic Neuroscience : Basic & Clinical·John B Furness
Jan 25, 2007·Expert Opinion on Investigational Drugs·Peter Holzer
Sep 18, 2007·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Kristina Johnell, Inga Klarin
Jan 11, 2008·International Journal of Clinical Pharmacology and Therapeutics·S I HaiderJ Fastbom
Mar 28, 2008·Alimentary Pharmacology & Therapeutics·S F CookS E Fehnel
Apr 18, 2008·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·J B Furness
May 30, 2008·The New England Journal of Medicine·Jay ThomasRobert J Israel
Aug 30, 2008·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Timothy J BellRussell Williamson
Apr 7, 2009·Regulatory Peptides·Peter Holzer
Jul 21, 2009·Expert Opinion on Drug Safety·Joseph V PergolizziErrol Gould
Aug 12, 2009·Journal of Pain & Palliative Care Pharmacotherapy·Sean D CandrilliShrividya Iyer
Oct 13, 2009·Clinical Pharmacokinetics·Shu-Feng Zhou
Jan 8, 2010·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Appavu ChandrasekaranJoAnn Scatina
Jan 27, 2010·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·A K TutejaA G Lipman
Feb 23, 2010·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Zeen TongJoAnn Scatina
Mar 4, 2010·The Annals of Pharmacotherapy·Winghan Jacqueline KwongShane Kavanagh
Apr 30, 2010·Drugs·Karly P Garnock-Jones, Kate McKeage
Jul 14, 2010·Pharmacoepidemiology and Drug Safety·Florence T BourgeoisKenneth D Mandl
Aug 24, 2010·Journal of Pain and Symptom Management·Frida HjalteCatharina Hjortsberg

❮ Previous
Next ❯

Citations

Sep 29, 2020·Therapeutics and Clinical Risk Management·Flaminia ColuzziPatrizia Romualdi
Jun 18, 2020·Journal of Pain Research·Flaminia ColuzziJoseph Pergolizzi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.